€2.4m contract for pan-European coronary study

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management services and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of a contract worth over €2.4 million to conduct a major international study into an innovative new heart treatment.

Working alongside Professor Keith Oldroyd of the Golden Jubilee National Hospital in Scotland, the study aims to determine whether the use of Percutaneous Coronary Intervention (PCI) with a new stent with a bio-absorbable coating could be used as an effective method for treating patients with disease in the left-main coronary artery in their heart.

Valued at over €2.4 million, the study will be conducted in five European countries over a two year period with Prof Oldroyd and Prof Robert-Jan van Guens from the prestigious Erasmus University in Rotterdam, Holland, serving as the co-principal investigators. Venn has unique experience in the management of investigator initiated studies, having previously worked with investigators on various trials throughout Europe.

Speaking about the contract, Venn CEO, Tony Richardson stated: "We are delighted to be part of this important study as it is an area of the business that we have focused on expanding in recent years. Our recent expansions and service additions allow us to supply the complete envelope of services for these studies whether they are single site or multi-country site studies. We are looking forward to working with the Professor Oldroyd and Prof Robert-Jan van Guens and contributing to advancing the research in such an important area.

"This contract follows on from the multi-country study signed up in May this year worth over €3m and demonstrates that our wider European footprint and expanded skill base allows us to target higher value studies such as these."

Discussing the trial, Professor Keith Oldroyd, one of the Principal Investigators, Consultant Cardiologist and Director of Research at the Golden Jubilee said: "The developments in PCI and stenting over the past 20 years have been absolutely incredible. The new stent we will be using in this trial has an innovative coating, which delivers a drug to prevent re-narrowing and over a period of three to four months, dissolves into two harmless components (carbon dioxide and water). This should dramatically improve the healing of the artery and will reduce the length of time a patient has to rely on blood thinning medication." 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla Mc Guinness, Marketing Manager

 

Tel: +594 694410116

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews/Andrew Jones(Corporate Finance)

Tel: +44 (0)161 831 1512

Dominic Wilson (Institutional Sales)

Tel: +44 (0)20 7533 7727

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.